AR126610A1 - Actividad biológica multidimensional optimizada de poli-iclc con tamaño y formulación de componentes controlados - Google Patents
Actividad biológica multidimensional optimizada de poli-iclc con tamaño y formulación de componentes controladosInfo
- Publication number
- AR126610A1 AR126610A1 ARP220102025A ARP220102025A AR126610A1 AR 126610 A1 AR126610 A1 AR 126610A1 AR P220102025 A ARP220102025 A AR P220102025A AR P220102025 A ARP220102025 A AR P220102025A AR 126610 A1 AR126610 A1 AR 126610A1
- Authority
- AR
- Argentina
- Prior art keywords
- poly
- iclc
- formulation
- biological activity
- component size
- Prior art date
Links
- 239000012648 POLY-ICLC Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 229940115270 poly iclc Drugs 0.000 title abstract 4
- 230000004071 biological effect Effects 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 108700002563 poly ICLC Proteins 0.000 abstract 3
- 208000025721 COVID-19 Diseases 0.000 abstract 2
- 208000037847 SARS-CoV-2-infection Diseases 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 101001082073 Homo sapiens Interferon-induced helicase C domain-containing protein 1 Proteins 0.000 abstract 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 abstract 1
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 abstract 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 239000012646 vaccine adjuvant Substances 0.000 abstract 1
- 229940124931 vaccine adjuvant Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Una molécula Poli-ICLC que comprende un componente Poli-I que tiene una longitud de aproximadamente 0,4 a 5 kilobases y un componente Poli-C que tiene una longitud de aproximadamente 2 a 8 kilobases. Reivindicación 5: La molécula de Poli-ICLC de las reivindicaciones de 1 a 3, o composición de las reivindicaciones 4, para uso en la profilaxis, profilaxis previa a la exposición, tratamiento y/o atenuación de síntomas inflamatorios de infecciones virales o microbianas. Reivindicación 6: La composición Poli-ICLC de la reivindicación 4, en donde la composición tiene efectos inmunomoduladores, adyuvantes de vacunas, antivirales y/o antiinflamatorios mediados por la activación de MDA5, TLR3 y otros sistemas enzimáticos dependientes de dsRNA. Reivindicación 17: Uso, según cualquiera de las reivindicaciones 10 u 11, en donde la infección viral es una infección por SARS-CoV-2. Reivindicación 18: Uso, según cualquiera de las reivindicaciones 10 u 11, en donde la infección viral es una infección por SARS-CoV-2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163259660P | 2021-07-30 | 2021-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126610A1 true AR126610A1 (es) | 2023-10-25 |
Family
ID=85088227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102025A AR126610A1 (es) | 2021-07-30 | 2022-07-29 | Actividad biológica multidimensional optimizada de poli-iclc con tamaño y formulación de componentes controlados |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR126610A1 (es) |
| WO (1) | WO2023009171A2 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7439349B2 (en) * | 2002-07-03 | 2008-10-21 | Andres Salazar | Method for preparation of large volume batches of poly-ICLC with increased biological potency; therapeutic, clinical and veterinary uses thereof |
| KR20230076867A (ko) * | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
| US10849921B2 (en) * | 2017-05-17 | 2020-12-01 | Bioncotech Therapeutics Sl | Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine |
-
2022
- 2022-07-29 AR ARP220102025A patent/AR126610A1/es unknown
- 2022-08-04 WO PCT/US2022/000015 patent/WO2023009171A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023009171A2 (en) | 2023-02-02 |
| WO2023009171A3 (en) | 2023-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022018819A2 (pt) | Vacinas contra coronavírus e métodos de uso | |
| CL2016000240A1 (es) | Composición inmunogénica de reovirus de peces (prv) que comprende ácido nucleico del prv; polipéptido; virus atenuado o inactivado del prv, uso de la composición inmunogénica que sirve para tratar afecciones de infeción por prv en un animal. | |
| BR112022017308A2 (pt) | Composição que compreende lactoferrina e cepas bacterianas probióticas para uso oral com ação antiviral | |
| CL2023001949A1 (es) | Anticuerpos que se dirigen al gp120 de vih y métodos de uso (divisional de solicitud de patente no. 3422-2020) | |
| BR112016026556A8 (pt) | inibidores de mek, de p38 e/ou de nfkb, seus usos, composição, sistema de teste in vitro, seu uso, e método para detecção de moléculas eficazes na profilaxia e/ou tratamento de uma co-infecção | |
| BRPI0720569B8 (pt) | compostos de tetraciclina substituída e uso dos ditos compostos para o tratamento de uma infecção bacteriana, viral ou parasitária | |
| AR118734A1 (es) | Formulaciones y métodos de vectores de virus adenoasociados | |
| NO20080913L (no) | HIV-revers-transriptaseinhibitorer | |
| BR112022021445A2 (pt) | Métodos e composições para tratar condições inflamatórias associadas com doença infecciosa | |
| AR030068A1 (es) | Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet | |
| BR112018014794A2 (pt) | pirimidinas substituídas com arila para uso em infecção pelo vírus influenza | |
| BR112023002951A2 (pt) | Compostos de fosfolipídio e usos destes | |
| BR112023001129A2 (pt) | Pró-fármacos antivirais, formulações farmacêuticas e métodos | |
| BR112022002123A2 (pt) | Composição farmacêutica para produzir uma quantidade segura de óxido nítrico e seu uso | |
| BR112022000957A2 (pt) | Uso de progestógeno para inibir tempestade de citocina e composição compreendendo progestógeno | |
| AR126610A1 (es) | Actividad biológica multidimensional optimizada de poli-iclc con tamaño y formulación de componentes controlados | |
| BR112022021423A2 (pt) | Uso de proteína surfactante d para tratar infecções virais | |
| CL2022002239A1 (es) | Tafoxiparina para el tratamiento de la preeclampsia | |
| UY39313A (es) | Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire | |
| MX2020003473A (es) | Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. | |
| AR106057A1 (es) | Composición con efecto antiviral, composición farmacéutica | |
| CU20200009A7 (es) | Composiciones para tratar y/o prevenir la infección por el virus de la hepatitis b | |
| BR112021020605A2 (pt) | Inibidor de mek para o tratamento de infecções virais e bacterianas | |
| BR112021022806A2 (pt) | Método para tratar a infecção crônica por hbv, sirna, usos de um sirna, e de um sirna e peg-ifna e de um sirna, peg-ifna e um nrti, método, composição para uso ou uso e kit | |
| BR112017019534A2 (pt) | substrato fibroso para captura de bacterias gram-negativas |